Drug Profile
Research programme: small molecule therapeutics - Amgen/Graffinity Pharmaceuticals
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Amgen; Graffinity
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in Germany
- 23 Mar 2010 Preclinical development is ongoing in Germany
- 11 Sep 2008 Preclinical development is ongoing Germany